03 · Frontier Science
The rise of GLP-1 microdosing
1 min readThe idea: step down to a small dose and stay there, so weight and muscle stop swinging with every stop and start.
Stopping a GLP-1 medicine usually brings the weight back, and that is the case being made for microdosing: stepping down to a small maintenance dose that holds the loss with less drug.
The worry is body composition. About a third of the weight lost on the earlier medicines is lean mass, mostly muscle, while what returns after stopping is mostly fat. Each cycle of stopping and restarting leaves a person with less muscle and more fat than before.
Microdosing is a clinician's proposal, not a tested protocol, and not everyone finds a dose that works. The next proof would be a trial comparing a low maintenance dose with stopping outright.
Read the full story at Huberman Lab ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
MOTS-C is a small peptide associated with mitochondria that has attracted attention in early research on metabolism
Weight loss drugs are being tested on overweight cats, starting with about 70
A designed enzyme shows where protein engineering is heading
